Organization | Multiple Myeloma Research Foundation

Multiple Myeloma Research Foundation Report issue

Foundation Phase 1 Phase 2

Founded: Norwalk CT United States (1998)

Organization Overview

First Clinical Trial

2011

NCT01410500

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2024

Timeline

NOW

Now

Alternative names

Multiple Myeloma Research Foundation

Active Ingredients

Drugs in Phase 2 Trials (9)

carfilzomib (kyprolis) (2 trials)

ciltacabtagene autoleucel (Carvykti) (1 trial)

dexamethasone (1 trial)

ixazomib (ninlaro) (2 trials)

lenalidomide (revlimid) (1 trial)

pomalidomide (pomalyst) (1 trial)

teclistamab (Tecvayli) (1 trial)

urea (2 trials)

venetoclax (venclexta) (1 trial)

Drugs in Phase 1 Trials (2)

durvalumab (imfinzi) (1 trial)

tremelimumab (Imjudo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 7
# of Trial APIs: 11